December 08, 2009 – Baltimore, MD.    Comprehensive Cancer Cell Diagnostics, Inc (CCCD), announced today that the Centers for Medicare & Medicaid will provide coverage for their Drug Response Indicator Test (DRIT), trademarked as the Breast Cancer DirectHit^TM Test Panel. In addition to Medicare, several other major health insurance companies have provided coverage for the test.

The DirectHit Panel™ Service analyzes an individual patient’s tumor in order to indicate the response to commonly prescribed anti-breast cancer chemotherapy drugs.  DirectHit™ provides information about the tumor that may be used in addition to the usual tests to prescribe the most effective anticancer drug treatment.

CCCD is a Baltimore, MD.  based pharmacodiagnostics company, formed in 2004 by a core group of former Johns Hopkins University researchers. The company’s mission is to aid physicians in establishing a personalized treatment regime for individual cancer patients. CCCD is dedicated to “saving lives and life savings.”   DirectHit™ is a trademark owned by CCCD.   For more information about CCCD, please visit the company’s website at www.cccdiag.com.